Dr Urmila Thatte, professor and former head of clinical pharmacology at the King Edward Memorial College, Mumbai, is among the 631,471 healthcare workers across India who have received one of two Covid-19 vaccines used in the nationwide campaign until Tuesday evening.
Dr Thatte, who has been on an expert advisory panel on drug evaluation for the World Health Organisation and a former secretary of the Forum for Ethics Review Committees in India, on Tuesday took the AstraZeneca-Oxford vaccine, Covishield. But she told
The Telegraph that she wishes she and all other beneficiaries had a choice.
I wish I had a choice. I wish all who get vaccinated have the option to choose between vaccines. Even in a pandemic, when there is an option to choose, we should get a choice.
120 volunteers for India safety study shots Trial nod for homegrown RNA vaccine The human safety test run in India will offer the candidate to 120 volunteers 60 in the 18-55 years age group, and 60 in the 56-75 years age group
Two years ago, Sanjay Singh, a biochemist and chief executive officer of a Pune-based biotechnology company producing drugs for cancers and strokes, turned his attention to a new “platform” to design personalised vaccines against breast cancer.
Singh, working with his long-term research collaborator in the US, Steve Reed, set out to design vaccines based on the genetic material called mRNA and tailored to stimulate patients’ immune systems into attacking their own breast tumour cells.